Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-cash Items: 2014-2024

Historic Non-cash Items for CytomX Therapeutics (CTMX) over the last 6 years, with Dec 2024 value amounting to $5.5 million.

  • CytomX Therapeutics' Non-cash Items fell 36.58% to $5.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.5 million, marking a year-over-year decrease of 36.58%. This contributed to the annual value of $10.6 million for FY2024, which is 21.84% up from last year.
  • Per CytomX Therapeutics' latest filing, its Non-cash Items stood at $5.5 million for Q4 2024, which was down 36.58% from $8.7 million recorded in Q4 2023.
  • CytomX Therapeutics' Non-cash Items' 5-year high stood at $8.7 million during Q4 2023, with a 5-year trough of $5.3 million in Q1 2021.
  • Its 3-year average for Non-cash Items is $7.2 million, with a median of $7.4 million in 2022.
  • Data for CytomX Therapeutics' Non-cash Items shows a peak YoY increase of 24.78% (in 2020) and a maximum YoY decrease of 80.24% (in 2020) over the last 5 years.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' Non-cash Items stood at $6.1 million in 2020, then fell by 1.48% to $6.1 million in 2021, then rose by 22.70% to $7.4 million in 2022, then rose by 16.73% to $8.7 million in 2023, then slumped by 36.58% to $5.5 million in 2024.
  • Its last three reported values are $5.5 million in Q4 2024, $8.7 million for Q4 2023, and $7.4 million during Q4 2022.